Investigation methylation status of tumor suppressor gene NR4A1 and NR4A3 and frequency of rs1569686 polymorphism of DNMT3B gene in patients with acute myeloid leukemia

Document Type : Original article

Authors

1 Department of Hematology and Blood Banking, School of Allied Medical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran

2 Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.

3 Hematologic Malignancies Reserch Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

4 Department of Medical Biotechnology, School of Medical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran

Abstract

Acute myeloid leukemia (AML) is the most frequent type of leukemia among adults. Investigating AML heterogeneity based on DNA methylation can improve clinical diagnosis and prognosis. This study was conducted to investigate NR4A1 and NR4A3 gene methylation in fifty newly diagnosed AML patients and fifty healthy controls using Methyl specific PCR (MSP). The frequency of the rs1569686 in the DNMT3B was also determined by Tetra primer ARMS PCR. Also, the association between methylation of studied genes and some prognostic marker including mutation of FLT3 and NPM genes, as well as some hematological factors of patients was evaluated. According to the findings, AML patients have a significantly higher prevalence of methylated NR4A1 and NR4A3 genes than those without AML. AML patients with un-methylated NR4A3 had significantly higher frequency of FLT-ITD positivity than AML patients with methylated NR4A3. Also, there was no significant association between rs1569686 and AML. Finally, the distribution of different genotypes of rs1569686 between AML patients with and without methylation in NR4A1 and NR4A3 did not show any significant association. The results found that NR4A1 and NR4A3 were hyper-methylated in AML patients. However, rs1569686 polymorphism was not a main contributor to methylation status of studied gene. Future studies should consider other mechanisms influencing the role of NR4A1 and NR4A3 hypermethylation in AML.

Keywords

References

  1. Ghaderzadeh M, Asadi F, Hosseini A, Bashash D, Abolghasemi H, Roshanpour A. Machine learning in detection and classification of leukemia using smear blood images: a systematic review. Sci Progr 2021;9933481.
  2. Amin AH, Al Sharifi LM, Kakhharov AJ, Opulencia MJC, Alsaikhan F, Bokov DO, Majdi HS, Jawad MA, Hammid AT, Shalaby MN, Mustafa YF, Siahmansouri H. Role of acute myeloid leukemia (AML)-derived exosomes in tumor progression and survival. Biomed Pharmacother 2022;150:113009.
  3. Dozzo A, Galvin A, Santo Scalia, O’Driscoll CM, Ryan KB. Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern. Drug Deliv Transl Res 2023:13:2110-2141.
  4. Abdallah M, Xie Z, Ready A, Manogna D, Mendler JH, Loh KP. Management of acute myeloid leukemia (AML) in older patients. Curr Oncol Rep 2020;22:130.
  5. Yeh CM, Chang LY, Lin SH, Chou JL, Hsieh HY, Zeng L-H, Chuang S-Y, Wang HW, Dittner C, Lin CY, Lin JMJ, Huang YT, Ng EKW, Cheng ASL, Wu SF, Lin J, Yeh KT, Chan MWY. Epigenetic silencing of the NR4A3 tumor suppressor, by aberrant JAK/STAT signaling, predicts prognosis in gastric cancer. Sci Rep 2016;6:31690.
  6. Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J, Conneely OM. Abrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute myeloid leukemia. Nat Med 2007;13:730-735.
  7. Crean D, Murphy EP. Targeting NR4A nuclear receptors to control stromal cell inflammation, metabolism, angiogenesis, and tumorigenesis. Front Cell and Dev Biol 2021; 9:589770.
  8. Nagaoka M, Yashiro T, Uchida Y, Ando T, Hara M, Arai H, Ogawa H, Okumura K, Kasakura K, Nishiyama C. The orphan nuclear receptor NR4A3 is involved in the function of dendritic cells. J Immunol 2017;199:2958-2967.
  9. Wenzl K, Troppan K, Neumeister P, Deutsch AJA. The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasms. Curr Drug Targets 2015;16:38-46.
  10. Barišić A, Kolak M, Peterlin A, Tul N, Gašparović Krpina M, Ostojić S, Peterlin B, Pereza N. DNMT3B rs1569686 and rs2424913 gene polymorphisms are associated with positive family history of preterm birth and smoking status. Croat Med J 2020;61:8-17.
  11. Sae-Lee C, Barrow TM, Colicino E, Choi SH, Rabanal-Ruiz Y, Green D, Korolchuk VI, Mathers JC, Byun HM. Genomic targets and selective inhibition of DNA methyltransferase isoforms. Clin Epigenetics 2022;14:103.
  12. Zhang H, Ying H, Wang X. Methyltransferase DNMT3B in leukemia. Leuk Lymphoma 2020;61:263-273.
  13. Zheng Q, Zeng TT, Chen J, Liu H, Zhang H, Su J. Association between DNA methyltransferases 3B gene polymorphisms and the susceptibility to acute myeloid leukemia in Chinese Han population. PLoS One 2013;8:e74626.
  14. Lin SC, Yao CY, Hsu CA, Lin CT, Calkins MJ, Kuo YY, Tang JL, Tien HF, Wu SJ. Functional association of NR4A3 downregulation with impaired differentiation in myeloid leukemogenesis. Ann Hematol 2022;101:2209-2218.
  15. Shimizu R, Muto T, Aoyama K, Choi K, Takeuchi M, Koide S, Hasegawa N, Isshiki Y, Togasaki E, Kawajiri-Manako C, Nagao Y, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Iseki T, Strczynowski DT, Iwama A, Yokote K, Nakaseko C. Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. Leuk Res 2016;50:85-94.
  16. Chen YT, Liao JW, Tsai YC, Tsai FJ. Inhibition of DNA methyltransferase 1 increases nuclear receptor subfamily 4 group A member 1 expression and decreases blood glucose in type 2 diabetes. Oncotarget 2016;7:39162-39172.
  17. Safe S, Karki K. The paradoxical roles of orphan nuclear receptor 4A (NR4A) in cancer. Mol Cancer Res 2021;19:180-191.
  18. Deutsch AJA, Rinner B, Knausz H, Linkesch W, Beham-Schmid C, Neumeister P. Ccytosporone-B induces NR4A1 meditated apoptosis in aggressive lymphoma cells. Blood 2010;116:467.
  19. Liu, Chengyin, Han Tang, Nana Hu, and Tianbao Li. Methylomics and cancer: the current state of methylation profiling and marker development for clinical care. Cancer Cell Int 2023;23:242
  20. Conway O'Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol 2014;2014:103175.
  21. Juliusson G, Jädersten M, Deneberg S, Lehmann S, Möllgård L, Wennström L, Antunovic P, Cammenga J, Lorenz F, Ölander E, Lazarevic VL, Höglund M. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Adv 2020;4:1094-1101.
  22. Vosberg S, Kerbs P, Jurinovic V, Metzeler KH, Amler S, Sauerland C, Görlich D, Berdel W, Braess J, Hiddemann W, Spiekermann K, Herold T. DNA methylation profiling of AML reveals epigenetic subgroups with distinct clinical outcome. Blood 2019;134:2715.
  23. Boujmia OKA, Nadifi S, Dehbi H, Lamchahab M, Quessar A. The influence of DNMT3A and DNMT3B gene polymorphisms on acute myeloid leukemia risk in a Moroccan population. Curr Res Transl Med 2020;68:191-195.
  24. Han SS, Chatterjee N. Review of statistical methods for gene-environment interaction analysis. Curr Epidemiol Rep 2018;5:39-45.
  25. Touala-Chaila Z, Abderrahmane RK, Kerroumi S, Yousfi MJ, Meroufel DN, Boudjema A. Association study of the polymorphisms rs2228611 of the DNMT1gene and rs1569686 of the DNMT3Bgene with bladder cancer development in a sample of the Algerian population. Mol Biol Res Commun 2024;13(2):65-72.
  26. Jian J, Yuan C, Ji C, Hao H, Lu F. DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features. Clin Exp Med 2023;23:2639-2649.

Files

Share

How to cite

Statistics